Livmarli sustains benefit for Alagille patients over 7 years: Trial data
Nearly all children with Alagille syndrome who received Mirum Pharmaceuticals’ Livmarli (maralixibat) for seven years as part of clinical studies continued to experience…
Margarida Maia, PhD, Science Writer — 
Articles by Margarida Maia
In NASH, VK2809 treatment reduces liver fat, fibrosis: Phase 2b trial
One year of treatment with Viking Therapeutics’ candidate VK2809 safely and effectively reduces liver fat content, damage, and scarring in adults with nonalcoholic steatohepatitis…
1st patient enrolled in WIND-PSC natural history study
The first patient has been enrolled in WIND-PSC, a global study to track the natural course of primary sclerosing cholangitis (PSC) and generate real-world…
EMA committee favors approval of Livmarli for PFIC in EU
Note: This story was updated July 9, 2024, to clarify Livmarli is approved in the U.S. for all PFIC forms, but not recommended for a…
HealthWell Foundation opens fund for MASH patients in US
The HealthWell Foundation, a charity that helps people who can’t afford to pay their medical bills, has started a new fund to support those…
Blood scores may help with ICP diagnosis, management: Study
Two scores calculated from blood biomarkers can accurately discriminate between pregnant women with intrahepatic cholestasis of pregnancy (ICP) and those without, and predict ICP-associated…
Rare liver cancer found in toddler with Alagille syndrome
A toddler boy with cirrhosis, or permanent liver scarring, due to Alagille syndrome developed a hepatoblastoma, a type of liver cancer that typically occurs…
Autoimmune hepatitis treatment zetomipzomib trial seeks patients
A Phase 2a clinical trial testing Kezar Life Sciences’ investigational therapy zetomipzomib in adults with autoimmune hepatitis who did not respond well to standard…
New mutations tied to rapidly progressing intrahepatic cholestasis
Researchers in China have identified five new mutations in the NR1H4 gene in three boys with progressive familial intrahepatic cholestasis type 5 (PFIC5) and…
UDCA plus elafibranor best for treatment-resistant PBC: Analysis
Combining ursodeoxycholic acid (UDCA) with elafibranor, an experimental oral therapy for primary biliary cholangitis (PBC), may be the best treatment combination at lessening signs…